- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05863195
Tester la chimiothérapie par pompe en plus de la chimiothérapie standard par rapport à la chimiothérapie standard seule pour les patients présentant des métastases hépatiques colorectales non résécables : l'essai PUMP
Une étude randomisée de phase III sur la thérapie systémique avec ou sans perfusion artérielle hépatique pour les métastases hépatiques colorectales non résécables : l'essai PUMP
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metastatic colorectal cancer to the liver, but it is only available at a small number of hospitals, and most of the time it is not used until standard chemotherapy stops working. Standard chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding HAI to standard chemotherapy may be effective in shrinking or stabilizing unresectable colorectal liver metastases.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Biologique: Bevacizumab
- Médicament: Fluorouracil
- Procédure: Magnetic Resonance Imaging
- Médicament: Capecitabine
- Biologique: Panitumumab
- Médicament: Oxaliplatin
- Médicament: Leucovorin
- Biologique: Cetuximab
- Médicament: Irinotecan
- Médicament: Floxuridine
- Procédure: Computed Tomography
- Procédure: Implantation
- Procédure: Intrahepatic Infusion Procedure
- Procédure: Single Photon Emission Computed Tomography
Description détaillée
PRIMARY OBJECTIVE:
I. To determine if patients with persistently unresectable colorectal liver metastases (CRLM) after treatment with first-line chemotherapy have improved overall survival (OS) with hepatic arterial infusion (HAI) and systemic chemotherapy versus systemic chemotherapy alone.
SECONDARY OBJECTIVES:
I. To determine whether there is a direct association between hepatic progression free survival (hPFS) and overall survival (OS) when patients are treated with HAI combined with systemic chemotherapy for unresectable CRLM.
II To determine the impact on progression free survival (overall, hepatic and extrahepatic) for patients with unresectable CRLM treated with HAI in combination with systemic chemotherapy.
III. To determine objective response rate (ORR) in the liver, defined as the proportion of patients achieving complete or partial response by Response Evaluation Criteria is Solid Tumors (RECIST) 1.1.
IV. To determine the rate of conversion to resectable disease, defined as the proportion of patients who successfully convert from unresectable to resectable status and undergo R0/R1 resection/ablation.
V. To determine the rate in which patients are intended to be treated with HAI but are deemed ineligible at the time of planned pump insertion due to detection of occult extrahepatic disease or unsuitable arterial anatomy (Intra-Operative Ineligibility, IOI).
VI. To determine the extent to which patient and disease-specific factors correlate with short- and long-term risk of HAI-specific complications.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo surgery to place the HAI pump within 6 weeks of randomization, followed by single photon emission computed tomography/computed tomography (SPECT/CT) on study. Patients then receive floxuridine via the HAI pump within 12 weeks of randomization on study. Patients also receive one of the following standard chemotherapy regimens per the treating physician within 16 weeks of randomization: FOLFOX (fluorouracil intravenously [IV], oxaliplatin IV, and leucovorin IV), FOLFIRI (fluorouracil IV, irinotecan IV, and leucovorin IV), or OX/IRI (oxaliplatin IV and irinotecan IV) with or without cetuximab IV and/or panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or magnetic resonance imaging (MRI) scans throughout the trial.
ARM B: Patients receive one of the following standard chemotherapy regimens per the treating physician within 6 weeks of randomization: FOLFOXIRI (fluorouracil IV, oxaliplatin IV, irinotecan IV, and leucovorin IV), FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV, panitumumab IV, and/or bevacizumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may receive capecitabine orally (PO) in substitution for fluorouracil at the discretion of the investigator and may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial.
After completion of treatment, patients follow up every 3 months for 2 years and then every 6 months for an additional 3 years.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Retiré
- University of Alabama at Birmingham Cancer Center
-
-
Arizona
-
Gilbert, Arizona, États-Unis, 85234
- Recrutement
- Banner MD Anderson Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 602-747-9738
-
Chercheur principal:
- Rajesh Ramanathan
-
Phoenix, Arizona, États-Unis, 85006
- Recrutement
- Banner-University Medical Center Phoenix
-
Contact:
- Site Public Contact
- E-mail: BannerResearch@bannerhealth.com
-
Chercheur principal:
- Rajesh Ramanathan
-
Sun City, Arizona, États-Unis, 85351
- Recrutement
- Banner Boswell Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 480-440-7458
- E-mail: BMDACCResearch@bannerhealth.com
-
Chercheur principal:
- Rajesh Ramanathan
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- UCHealth University of Colorado Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 720-848-0650
-
Chercheur principal:
- Alexis D. Leal
-
-
Florida
-
Aventura, Florida, États-Unis, 33180
- Recrutement
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Chercheur principal:
- Jashodeep Datta
-
Contact:
- Site Public Contact
- Numéro de téléphone: 954-461-2180
-
Coral Gables, Florida, États-Unis, 33146
- Recrutement
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Chercheur principal:
- Jashodeep Datta
-
Contact:
- Site Public Contact
- Numéro de téléphone: 305-243-2647
-
Deerfield Beach, Florida, États-Unis, 33442
- Recrutement
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Chercheur principal:
- Jashodeep Datta
-
Contact:
- Site Public Contact
- Numéro de téléphone: 305-243-2647
-
Hollywood, Florida, États-Unis, 33021
- Recrutement
- UM Sylvester Comprehensive Cancer Center at Hollywood
-
Chercheur principal:
- Jashodeep Datta
-
Contact:
- Site Public Contact
- Numéro de téléphone: 305-243-2647
-
Miami, Florida, États-Unis, 33136
- Recrutement
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Chercheur principal:
- Jashodeep Datta
-
Contact:
- Site Public Contact
- Numéro de téléphone: 305-243-2647
-
Miami, Florida, États-Unis, 33176
- Recrutement
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Chercheur principal:
- Jashodeep Datta
-
Contact:
- Site Public Contact
- Numéro de téléphone: 305-243-2647
-
Plantation, Florida, États-Unis, 33324
- Recrutement
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Chercheur principal:
- Jashodeep Datta
-
Contact:
- Site Public Contact
- Numéro de téléphone: 305-243-2647
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Emory University Hospital/Winship Cancer Institute
-
Contact:
- Site Public Contact
- Numéro de téléphone: 404-778-1868
-
Chercheur principal:
- Olumide B. Gbolahan
-
Atlanta, Georgia, États-Unis, 30342
- Recrutement
- Emory Saint Joseph's Hospital
-
Chercheur principal:
- Olumide B. Gbolahan
-
Contact:
- Site Public Contact
- Numéro de téléphone: 404-851-7115
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Chercheur principal:
- Ryan Merkow
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Northwestern University
-
Contact:
- Site Public Contact
- Numéro de téléphone: 312-695-1301
- E-mail: cancer@northwestern.edu
-
Chercheur principal:
- Shishir K. Maithel
-
Chicago, Illinois, États-Unis, 60641
- Recrutement
- Northwestern Medicine Cancer Center Old Irving Park
-
Chercheur principal:
- Shishir K. Maithel
-
Contact:
- Site Public Contact
- E-mail: nctnprogram_rhlccc@northwestern.edu
-
Shiloh, Illinois, États-Unis, 62269
- Retiré
- Memorial Hospital East
-
-
Indiana
-
Carmel, Indiana, États-Unis, 46032
- Recrutement
- IU Health North Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 317-278-5632
- E-mail: iutrials@iu.edu
-
Chercheur principal:
- Anita Turk
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Indiana University/Melvin and Bren Simon Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 317-278-5632
- E-mail: iutrials@iu.edu
-
Chercheur principal:
- Anita Turk
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536
- Recrutement
- University of Kentucky/Markey Cancer Center
-
Chercheur principal:
- Michael J. Cavnar
-
Contact:
- Site Public Contact
- Numéro de téléphone: 859-257-3379
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- University of Michigan Rogel Cancer Center
-
Chercheur principal:
- Benjamin D. Ferguson
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-865-1125
- E-mail: CancerAnswerLine@med.umich.edu
-
Grand Rapids, Michigan, États-Unis, 49503
- Recrutement
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Chercheur principal:
- Kathleen Y. Butler
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- Recrutement
- University of Minnesota/Masonic Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 612-624-2620
-
Chercheur principal:
- Ajay Prakash
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Mayo Clinic in Rochester
-
Contact:
- Site Public Contact
- Numéro de téléphone: 855-776-0015
-
Chercheur principal:
- Cornelius A. Thiels
-
-
Missouri
-
City of Saint Peters, Missouri, États-Unis, 63376
- Retiré
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, États-Unis, 63141
- Retiré
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, États-Unis, 63110
- Retiré
- Washington University School of Medicine
-
St Louis, Missouri, États-Unis, 63129
- Retiré
- Siteman Cancer Center-South County
-
St Louis, Missouri, États-Unis, 63136
- Retiré
- Siteman Cancer Center at Christian Hospital
-
-
New Jersey
-
Basking Ridge, New Jersey, États-Unis, 07920
- Recrutement
- Memorial Sloan Kettering Basking Ridge
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-639-7592
-
Chercheur principal:
- Andrea Cercek
-
Middletown, New Jersey, États-Unis, 07748
- Recrutement
- Memorial Sloan Kettering Monmouth
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-639-7592
-
Chercheur principal:
- Andrea Cercek
-
Montvale, New Jersey, États-Unis, 07645
- Recrutement
- Memorial Sloan Kettering Bergen
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-639-7592
-
Chercheur principal:
- Andrea Cercek
-
-
New York
-
Buffalo, New York, États-Unis, 14263
- Recrutement
- Roswell Park Cancer Institute
-
Chercheur principal:
- Anuradha Krishnamurthy
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Commack, New York, États-Unis, 11725
- Recrutement
- Memorial Sloan Kettering Commack
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-639-7592
-
Chercheur principal:
- Andrea Cercek
-
East White Plains, New York, États-Unis, 10604
- Recrutement
- Memorial Sloan Kettering Westchester
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-639-7592
-
Chercheur principal:
- Andrea Cercek
-
New York, New York, États-Unis, 10065
- Recrutement
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-639-7592
-
Chercheur principal:
- Andrea Cercek
-
New York, New York, États-Unis, 10029
- Recrutement
- Mount Sinai Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-824-7309
- E-mail: CCTO@mssm.edu
-
Chercheur principal:
- James O. Park
-
Uniondale, New York, États-Unis, 11553
- Recrutement
- Memorial Sloan Kettering Nassau
-
Contact:
- Site Public Contact
- Numéro de téléphone: 212-639-7592
-
Chercheur principal:
- Andrea Cercek
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke University Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 888-275-3853
-
Chercheur principal:
- Hope E. Uronis
-
Raleigh, North Carolina, États-Unis, 27609
- Recrutement
- Duke Cancer Center Raleigh
-
Chercheur principal:
- Hope E. Uronis
-
Contact:
- Site Public Contact
- E-mail: NCTNStudyTeam@dm.duke.edu
-
Winston-Salem, North Carolina, États-Unis, 27157
- Recrutement
- Wake Forest University Health Sciences
-
Chercheur principal:
- Perry Shen
-
Contact:
- Site Public Contact
- Numéro de téléphone: 336-713-6771
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Actif, ne recrute pas
- Case Western Reserve University
-
Columbus, Ohio, États-Unis, 43210
- Recrutement
- Ohio State University Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-293-5066
- E-mail: Jamesline@osumc.edu
-
Chercheur principal:
- Alex B. Blair
-
Youngstown, Ohio, États-Unis, 44501
- Recrutement
- Saint Elizabeth Youngstown Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Chercheur principal:
- Howard M. Gross
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Recrutement
- Oregon Health and Science University
-
Contact:
- Site Public Contact
- Numéro de téléphone: 503-494-1080
- E-mail: trials@ohsu.edu
-
Chercheur principal:
- Skye C. Mayo
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Recrutement
- Lehigh Valley Hospital-Cedar Crest
-
Contact:
- Site Public Contact
- Numéro de téléphone: 610-402-9543
- E-mail: Morgan_M.Horton@lvhn.org
-
Chercheur principal:
- Tareq Al baghdadi
-
Erie, Pennsylvania, États-Unis, 16544
- Recrutement
- Saint Vincent Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 814-452-5000
-
Chercheur principal:
- Patrick L. Wagner
-
Jefferson Hills, Pennsylvania, États-Unis, 15025
- Recrutement
- Jefferson Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 412-359-3043
- E-mail: ddefazio@wpahs.org
-
Chercheur principal:
- Patrick L. Wagner
-
Monroeville, Pennsylvania, États-Unis, 15146
- Recrutement
- Forbes Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 412-858-7746
-
Chercheur principal:
- Patrick L. Wagner
-
Philadelphia, Pennsylvania, États-Unis, 19111
- Recrutement
- Fox Chase Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 215-728-4790
-
Chercheur principal:
- Vanessa Wookey
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- Recrutement
- West Penn Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 412-578-5000
-
Chercheur principal:
- Patrick L. Wagner
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Recrutement
- Allegheny General Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 877-284-2000
-
Chercheur principal:
- Patrick L. Wagner
-
Wexford, Pennsylvania, États-Unis, 15090
- Recrutement
- Wexford Health and Wellness Pavilion
-
Contact:
- Site Public Contact
- E-mail: Dawnmarie.DeFazio@ahn.org
-
Chercheur principal:
- Patrick L. Wagner
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Recrutement
- Vanderbilt University/Ingram Cancer Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-811-8480
-
Chercheur principal:
- Chandrasekhar Padmanabhan
-
-
Texas
-
Dallas, Texas, États-Unis, 75390
- Recrutement
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contact:
- Site Public Contact
- Numéro de téléphone: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Chercheur principal:
- Adam C. Yopp
-
Dallas, Texas, États-Unis, 75235
- Recrutement
- Parkland Memorial Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 214-590-5582
- E-mail: canceranswerline@UTSouthwestern.edu
-
Chercheur principal:
- Adam C. Yopp
-
Dallas, Texas, États-Unis, 75237
- Recrutement
- UT Southwestern Simmons Cancer Center - RedBird
-
Chercheur principal:
- Adam C. Yopp
-
Contact:
- Site Public Contact
- Numéro de téléphone: 214-648-7097
- E-mail: canceranswerline@utsouthwestern.edu
-
Fort Worth, Texas, États-Unis, 76104
- Recrutement
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Contact:
- Site Public Contact
- Numéro de téléphone: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Chercheur principal:
- Adam C. Yopp
-
Richardson, Texas, États-Unis, 75080
- Recrutement
- UT Southwestern Clinical Center at Richardson/Plano
-
Contact:
- Site Public Contact
- Numéro de téléphone: 972-669-7044
- E-mail: Suzanne.cole@utsouthwestern.edu
-
Chercheur principal:
- Adam C. Yopp
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53792
- Recrutement
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Chercheur principal:
- Patrick Varley
-
Madison, Wisconsin, États-Unis, 53718
- Recrutement
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Contact:
- Site Public Contact
- Numéro de téléphone: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Chercheur principal:
- Patrick Varley
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patient must be >= 18 years of age
-
Patient must have confirmed unresectable liver confined metastatic colorectal cancer (CRC).
-
Patient must not have radiographically or clinically evident extrahepatic disease (including but not limited to radiographically positive periportal lymph nodes).
- NOTE: Patients found to have positive periportal nodes at the time of HAI placement can remain on study.
-
Patient may have calcified pulmonary nodules, and/or =< 5 indeterminate and stable (for a minimum of 3 months on chemotherapy) pulmonary nodules each measuring =< 6 mm in maximal axial dimension.
-
Patient's primary tumor may be in place
-
-
Patient must have received previous first-line chemotherapy that meets one of the following three criteria: a) have received at least 6 but no more than 12 cycles of first-line cytotoxic chemotherapy (where 1 cycle = 14 days) OR b) have received at least 4 but no more than 8 cycles of first-line cytotoxic chemotherapy (where 1 cycle = 21 days) OR c) have developed new colorectal liver metastases (CRLM) within 12 months of completing adjuvant systemic therapy for stage II-III colorectal cancer.
- NOTE: First-line chemotherapy may have included any of the following regimens as listed in the National Comprehensive Cancer Network (NCCN) Guidelines: leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX) (or equivalent), leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan (FOLFIRI) (or equivalent), leucovorin calcium (calcium folinate), 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI), each with or without any of the following: bevacizumab, cetuximab, or panitumumab
-
Patient must have measurable disease
-
Patients who have disease progression, in the judgement of the treating multidisciplinary team, are not eligible.
- This requirement does not apply to patients who developed new colorectal liver metastases within 12 months of completing adjuvant systemic therapy for stage II-III colorectal cancer
-
Patient must meet the following criteria for technical unresectability:
- A margin-negative resection requires resection of three hepatic veins, both portal veins, or the retrohepatic vena cava OR a resection that leaves less than two adequately perfused and drained segments.
- NOTE: Institutional multidisciplinary review is required to confirm unresectability and rule out radiographically positive extrahepatic disease.
- NOTE: Patients who are deemed technically resectable but simultaneous biologically unresectable are not eligible.
-
Patient must undergo multiphase imaging of the chest, abdomen, and pelvis inclusive of CT and/or MRI angiography to confirm acceptable hepatic arterial anatomy for HAI and to rule out extrahepatic disease within 28 days prior to randomization.
- NOTE: If the patient had remote liver-arterial phase imaging greater than 4 weeks from randomization, then only a single phase (portal venous) intravenous contrasted staging CT and/or MRI of the chest/abdomen/pelvis is required.
-
Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 and be clinically fit to undergo surgery as determined by the pre-operative evaluation.
-
Patient must not have a liver tumor burden exceeding 70% of total liver volume.
-
Patient must not have had prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 2 weeks prior to randomization).
-
Patient must not have had prior trans-arterial bland embolization, chemoembolization (TACE) or radioembolization (TARE).
-
Patient must not have had prior treatment with HAI/floxuridine (FUDR)
-
Patient must not have microsatellite instability-high (MSI-H) colorectal cancer.
-
Patient must not have CRLM that could be resected with 2-stage hepatectomy, including associating liver partition and portal vein ligation (ALPPS).
-
Patient must not have an active infection, serious or non-healing active wound, ulcer, or bone fracture.
-
Patient must not have any serious medical problems which would preclude receiving the protocol treatment or would interfere with the cooperation with the requirements of this trial.
-
Patient must not have cirrhosis and/or clinical or radiographic evidence of portal hypertension
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study.
-
Leukocytes >= 3,000/mcL (obtained =< 28 days prior to protocol randomization)
-
Absolute neutrophil count (ANC) >= 1,500/mcL (obtained =< 28 days prior to protocol randomization)
-
Platelets >= 100,000/mcL (obtained =< 28 days prior to protocol randomization)
-
Total Bilirubin =< 1.5 mg/dL (obtained =< 28 days prior to protocol randomization)
-
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 3.0 x institutional upper limit of normal (ULN) (obtained =< 28 days prior to protocol randomization)
-
Creatinine =< 1.5 x institutional ULN OR creatinine clearance >= 50 mL/min calculated by the Cockcroft-Gault method (obtained =< 28 days prior to protocol randomization)
-
Calcium >= institutional lower limit of normal (LLN)
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial. Testing for HIV is not required for entry onto the study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm A (HAI, floxuridine, standard chemotherapy)
Patients undergo surgery to place the HAI pump within 6 weeks of randomization, followed by single SPECT/CT on study. Patients then receive floxuridine via the HAI pump within 12 weeks of randomization on study. Patients also receive one of the following standard chemotherapy regimens per the treating physician within 16 weeks of randomization: FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV and/or panitumumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial. |
Given IV
Autres noms:
Undergo MRI
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Given IV Given via HAI pump
Autres noms:
Undergo SPECT/CT and/or CT
Autres noms:
Undergo surgery to place the HAI pump Undergo HAI
Autres noms:
Undergo SPECT/CT
Autres noms:
|
|
Comparateur actif: Arm B (standard chemotherapy)
Patients receive one of the following standard chemotherapy regimens per the treating physician within 6 weeks of randomization: FOLFOXIRI IV, FOLFOX IV, FOLFIRI IV, or OX/IRI IV with or without cetuximab IV, panitumumab IV, and/or bevacizumab IV on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may receive capecitabine PO in substitution for fluorouracil at the discretion of the investigator and may have leucovorin omitted from their regimen per institutional standards. Patients also undergo CT and/or MRI scans throughout the trial. |
Given IV
Autres noms:
Given IV
Autres noms:
Undergo MRI
Autres noms:
Given PO
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Given IV Undergo SPECT/CT and/or CT
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall survival (OS)
Délai: From randomization to death from any cause, assessed up to 5 years
|
Patients still living will be censored at the date last known alive. OS will be evaluated using the Kaplan-Meier method, and arms will be compared via a stratified log rank test. |
From randomization to death from any cause, assessed up to 5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression free survival (PFS)
Délai: From randomization to first observed disease progression at any site, or death from any cause, assessed up to 5 years
|
Patients still living without disease progression will be censored at the date of last disease assessment. Disease progression will be based on findings from surveillance cross-sectional imaging of the chest/abdomen/pelvis every 3 months after randomization, defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed similarly to OS, but with and without stratification for sensitivity. |
From randomization to first observed disease progression at any site, or death from any cause, assessed up to 5 years
|
|
Hepatic PFS
Délai: From randomization to first observed disease progression in the liver, or death from any cause, assessed up to 5 years
|
Patients still living without hepatic disease progression will be censored at the date of last disease assessment. Hepatic disease progression will be based on findings from surveillance cross-sectional imaging of the chest/abdomen/pelvis every 3 months after randomization, defined by RECIST 1.1. |
From randomization to first observed disease progression in the liver, or death from any cause, assessed up to 5 years
|
|
Extrahepatic-PFS
Délai: From randomization to first observed disease progression outside of the liver, or death from any cause, assessed up to 5 years
|
Patients still living without extrahepatic disease progression will be censored at the date of last disease assessment. Extrahepatic disease progression will be based on findings from surveillance cross-sectional imaging of the chest/abdomen/pelvis every 3 months after randomization, defined by RECIST 1.1. |
From randomization to first observed disease progression outside of the liver, or death from any cause, assessed up to 5 years
|
|
Objective response rate
Délai: Up to 5 years
|
Will assess hepatic disease burden specifically. Defined as the proportion of patients achieving complete or partial response by RECIST 1.1. Response will be based on surveillance cross-sectional imaging of the chest/abdomen/pelvis every 3 months (+/- 2 weeks) from randomization. Arms will be compared via a Pearson chi-square test. All rates will be reported with exact binomial 95% confidence intervals. |
Up to 5 years
|
|
Rate of conversion to resectable disease
Délai: Up to 5 years
|
Defined as the proportion of patients who successfully convert from unresectable to resectable status and undergo R0/R1 resection/ablation. All rates will be reported with exact binomial 95% confidence intervals. |
Up to 5 years
|
|
Intra-operative ineligibility rate
Délai: Up to 5 years
|
Defined as the proportion of patients intended to receive hepatic arterial infusion that do not undergo pump implantation due to intraoperative detection of occult extrahepatic disease or unsuitable hepatic arterial anatomy. All rates will be reported with exact binomial 95% confidence intervals. |
Up to 5 years
|
|
Incidence of adverse events
Délai: Up to 5 years
|
Defined according to the Common Terminology Criteria for Adverse Events. |
Up to 5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Michael Lidsky, ECOG-ACRIN Cancer Research Group
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies intestinales
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs intestinales
- Maladies rectales
- Maladies du côlon
- Tumeurs colorectales
- Acides aminés, peptides et protéines
- Protéines
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Préparations pharmaceutiques
- Techniques d'investigation
- Formulaires de dosage
- Acides nucléiques, nucléotides et nucléosides
- Phénomènes physiques
- Camptothécine
- Alcaloïdes
- Enzymes et coenzymes
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Produits chimiques inorganiques
- Complexes de coordination
- Désoxycytidine
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Techniques de chimie, analytique
- Analyse du spectre
- Nucléosides
- Formyltétrahydrofolate
- Tétrahydrofolat
- Acide folique
- Pterines
- Ptéridines
- Uracile
- Pyrimidinones
- Coenzymes
- Isotypes d'immunoglobulines
- Sulfures
- Anions
- Ions
- Électrolytes
- Sulfure d'hydrogène
- Phénomènes électromagnétiques
- Phénomènes magnétiques
- Désoxyribonucléosides
- Rayonnement électromagnétique
- Radiation
- Rayonnement, ionisant
- Particules élémentaires
- Lumière
- Phénomènes optiques
- Rayonnement, non ionisant
- Désoxyuridine
- Uridine
- Préparations d'action retardée
- Capécitabine
- Oxaliplatine
- Bévacizumab
- Irinotécan
- Panitumumab
- Cétuximab
- Fluorouracile
- Leucovorine
- Immunoglobuline G
- Floxuridine
- Spectroscopie de résonance magnétique
- Disulfures
- Rayons X
- Photons
- déshydroftorafur
- (225) AC-DOTA-C (RGDYK)
- 5-fluoro-2'-désoxyuridine
- Implants de drogue
Autres numéros d'identification d'étude
- EA2222
- U10CA180820 (Subvention/contrat des NIH des États-Unis)
- EA2222 (Autre identifiant: CTEP)
- NCI-2023-02357 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- EA2222 (Autre identifiant: ECOG-ACRIN Cancer Research Group)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .